Kevin Bottomley

Managing Director, Europe
Healthcare

Kevin joined the firm in 2012 in response to client demand for a dedicated healthcare practice. Kevin has over 30 years’ experience working in the healthcare sector, principally with pharmaceutical, biotechnology, business consultancy and M&A transaction advisory companies. He has been involved in the successful transaction of many businesses, acting as advisor to investors, major pharmaceutical, biotechnology as well as service companies to the life sciences industries.

During his career Kevin has held senior positions in pharmaceutical research, alliance management, business development and transactions. He has worked at Hoechst (Sanofi), Quintiles (IQVIA), Roche Pharmaceuticals, Inpharmatica and PharmaVentures.

Outside of work, Kevin is kept busy walking his two Shetland sheep dogs round the Chiltern Hills.

Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less. ― Marie Curie

Latest Insights

Corporate News
3rd August 2022

We are joining forces with Canaccord Genuity

We are very excited to share that we have agreed to join forces with Canaccord Genuity – a leading full-service investment bank serving growth companies in the middle market.  This is an important milestone in our journey and we wanted to update you on why we’ve taken this decision and what it means for you. […]

Insights
24th May 2022

Crossrail opens – a big day for travellers to and workers in London

At Results Healthcare we execute transactions around the world, with active projects in North America, Europe and Asia Pacific, so we see ourselves as a global organisation with offices and employees in London and New York, so a blog on transport in London might seem oddly parochial, but the opening of Crossrail, or the Elizabeth […]

Insights
28th March 2022

The growing impact of Environmental, Social, and Governance (“ESG”) on pharmaceutical supply chains.

The Russian invasion of Ukraine has been touted as the final nail in the coffin of globalisation, confirming the nationalisation of key industries and products. With respect to pharmaceutical manufacturing, this is accelerating a trend which has been ongoing for 10 years, the repatriation of drug manufacturing from Asia to the US and Europe has […]

Insights
23rd February 2022

Discovery CROs: what is the “balanced business model” and how is this valued?

Discovery Contract Research Organisations (“CROs”) essentially provide lab-based discovery services such as medicinal chemistry, biological screening etc to pharma companies and biotech, and this business segment has exploded in size, sophistication and value in recent years and is now a focus of both M&A and PE investment. This is covered in our forthcoming white paper […]

Insights
19th January 2022

Predictions for Life Sciences Industries for 2022, and no ‘San Francisco’ This Year!

The Covid 19 pandemic continues to have a major impact on the healthcare industry, both positive if you are close to the discovery and provision of treatments for this infection and negative if you are selling certain other drugs, such as antibiotics or providing care services, which have been negatively impacted by this pandemic. However, […]

Insights
19th August 2020

Rising to the challenge: the response of UK biopharmaceuticals to the COVID-19 pandemic

Hindsight is a gift that every politician desires and with it, perhaps we would have been better prepared for the COVID-19 pandemic, acted more quickly, with greater certainty and ultimately more effectively. Given that this is a new disease, which was first characterised at the end of 2019, the UK biopharma industry (and the global […]

Insights
23rd April 2020

Will the spin-off of Sanofi pharmaceutical chemistry manufacturing happen now?

Earlier in 2020 in a pre-COVID-19 world, Sanofi announced its intention to spin off a significant part of their chemistry manufacturing capability with Sanofi sites in Brindisi, Italy; Frankfurt, Germany; Haverhill, England; St. Aubin les Elbeuf, France; Upjest, Hungary; and Vertolaye, France, forming a new company separated from Sanofi (but with Sanofi aspiring to own […]

Insights
14th April 2020

Life sciences supply chain resilience: now and post Covid-19

Without a doubt, life sciences supply chain resilience will be markedly different post Covid-19. There will be a massive restructuring generally of supply chains for strategic products such as drugs, diagnostics, personal safety equipment, food, chemicals etc., driven by national governmental actions in response to the Covid-19 pandemic. On the positive side, researchers have come […]

Corporate News
3rd April 2020

Exceptional circumstances call for exceptional support

During these uncertain times, we are all working hard to equip our businesses to survive and thrive in a very challenging economic environment. In our experience, the response window is short and learning from the successes and failures of others, vital. Each member of our senior team has spent between 15 and 40 years working […]